Cargando…
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observation...
Autores principales: | Tamez-Perez, Héctor Eloy, Delgadillo-Esteban, Enrique, Soni-Duque, David, Hernández-Coria, Mayra Ivonne, Tamez-Peña, Alejandra Lorena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493113/ https://www.ncbi.nlm.nih.gov/pubmed/28680862 http://dx.doi.org/10.1186/s40200-017-0308-4 |
Ejemplares similares
-
Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015) -
El ABC de la medicina científica
por: Tamez Pérez, Héctor Eloy
Publicado: (2012) -
Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022) -
OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019) -
Rosiglitazone as an option for patients with acromegaly: a case series
por: Tamez-Pérez, Héctor E, et al.
Publicado: (2011)